Skip to content
Review Open access

Counteracting Influenza Virus Evolution Through the Full Spectrum of Broadly Protective Antibodies

Jul 2026 · Immunological Reviews · Vol 341 · 1 citation · 213 references
Medicine

TL;DR

Current knowledge of broadly protective flu antibodies is summarized and how mechanistic and structural insights can guide the development of next‐generation influenza vaccines that offer broad‐spectrum protection against antigenically diverse viruses is discussed.

Abstract

Despite the presence of licensed vaccines and therapeutics, influenza viruses remain a major public health concern, as they cause seasonal respiratory infections and pose a pandemic threat through the emergence of zoonotic strains. Although neutralizing antibodies elicited by seasonal vaccination constitute a primary defense against infection, their protective capacity is often limited because they frequently target the epitopes that are highly susceptible to structural changes through viral evolution. To overcome this challenge, broadly protective antibodies have been intensively investigated in both humans and animal models. These antibodies recognize conserved epitopes and confer protection through multiple mechanisms beyond conventional neutralization. Recent advances in antibody discovery technologies and structural biology have enabled high‐resolution mapping of conserved epitopes and the on‐target antibodies that bind them. Furthermore, although broadly protective antibodies are typically elicited only at low frequencies following standard vaccination, several settings have been reported in which their induction is enhanced. Those findings increase the feasibility of epitope‐focused vaccine strategies for enhancing the breadth and durability of antibody responses. In this review, we summarize current knowledge of broadly protective flu antibodies and discuss how mechanistic and structural insights can guide the development of next‐generation influenza vaccines that offer broad‐spectrum protection against antigenically diverse viruses.

Read PDF

Similar papers

Review Open access Aug 2026

Some Exposure for Influenza Hemagglutinin Interface Antibodies

Influenza viruses are a constant threat to human health. Current vaccines often confer low to moderate protection against infection with seasonal viruses and little‐to‐no protection against pandemic viruses. Improved vaccines are needed. These vaccines will need to reliably elicit antibodies to conserved sites that are...

Kevin R. McCarthy · 0 citations
Review Open access Sep 2026

Antibody-based therapies against Andes virus: from neutralization to Fc-mediated protection

Andes virus, the principal etiological agent of hantavirus cardiopulmonary syndrome in South America, is a zoonotic pathogen associated with case fatality rates of up to 40%. Despite its high clinical burden and unique capacity for person-to-person transmission among hantaviruses, no licensed vaccines or specific ant...

Jorge T. González, Camila Kossack, Jose L. Garrido et al. · 0 citations
Open access Sep 2026

Broadly reactive antibodies against influenza B virus hemagglutinin neutralize and protect through distinct structural mechanisms

ABSTRACT Influenza B viruses contribute substantially to seasonal disease burden; however, the structural basis by which antibodies recognize the major glycoprotein hemagglutinin (HA) and mediate antiviral activity remains incompletely defined. Influenza B virus used to circulate as two antigenically distinct lineages,...

D. Bhavsar, Alesandro Civljak, Bruno Bonnettaz et al. · 0 citations
Review Open access Aug 2026

Population Immunity to Influenza Neuraminidase: From Immune Imprinting to Pandemic Preparedness

Neuraminidase (NA) is a major surface glycoprotein of influenza viruses that mediates the release of progeny virions from infected cells. Although both hemagglutinin (HA) and NA are targets of protective immune responses, current seasonal influenza vaccines are primarily standardized based on HA content, resulting in v...

Kong Yen Liew, T. K. Sari, Y. Tan · 0 citations
Review Open access Sep 2026

Dengue Vaccines: Bridging Innovation and Public Health

Dengue is among the fastest-growing mosquito-borne viral infections worldwide and continues to pose a major public health challenge because no approved antiviral treatment is available. As a result, vaccination has become a cornerstone of dengue prevention. Several vaccine candidates have progressed through clinical de...

Vydeti Mounika, E. Sirisha, Srikakulapu Balu et al. · 0 citations
Review Open access Sep 2026

Functional antibody responses and protection against symptomatic dengue

Exposure to dengue virus (DENV) triggers the development of anti-viral antibodies that may contribute to either protection or disease progression. Antibodies exist in different isotypes and subtypes, with diverse specificities and functions. IgG antibodies are produced during primary and secondary DENV infections, wher...

C. L. Chua, H. T. M. Vo, C. B. L. Victorio et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.